1. Formulation Development and Improved Stability of a Combination Measles and Rubella Live-Viral Vaccine Dried for Use in the NanopatchTM Microneedle Delivery System
- Author
-
David B. Volkin, Angus Forster, Christopher Bird, Vineet Gupta, Swathi R. Pullagurla, Ying Wan, Paul Fahey, and Sangeeta B. Joshi
- Subjects
Pharmacology ,Infectivity ,business.industry ,Viral Vaccine ,030231 tropical medicine ,Immunology ,Excipient ,Context (language use) ,medicine.disease ,Virology ,Rubella ,Measles ,Dosage form ,03 medical and health sciences ,Titer ,0302 clinical medicine ,Immunology and Allergy ,Medicine ,030212 general & internal medicine ,business ,medicine.drug - Abstract
Measles (Me) and rubella (Ru) viral diseases are targeted for elimination by ensuring a high level of vaccination coverage worldwide. Less costly, more convenient MeRu vaccine delivery systems should improve global vaccine coverage, especially in low - and middle - income countries (LMICs). In this work, we examine formulating a live, attenuated Me and Ru combination viral vaccine with Nanopatch™, a solid polymer micro-projection array for intradermal delivery. First, high throughput, qPCR-based viral infectivity and genome assays were established to enable formulation development to stabilize Me and Ru in a scaled-down, custom-built evaporative drying system to mimic the Nanopatch™ vaccine coating process. Second, excipient screening and optimization studies identified virus stabilizers for use during the drying process and upon storage in the dried state. Finally, a series of real-time and accelerated stability studies identified eight candidate formulations that met a target thermal stability criterion for live vaccines (
- Published
- 2021
- Full Text
- View/download PDF